AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26066384 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg intravenous
Number of subjects: 86
Study 26066384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 23497021 — intervention group
Group type: EXPERIMENTAL
Intervention: BiPAP S/T with AVAPS
Number of subjects: 22
Study 23497021 — intervention group
Group type: COMPARATOR
Intervention: BiPAP S/T
Number of subjects: 22
Study 21576560 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS with a computer‐assisted surgery system
Number of subjects: 15
Study 21576560 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS without a computer‐assisted surgery system
Number of subjects: 15
Study 21576560 — intervention group
Group type: COMPARATOR
Intervention: Control day (nonsurgical day)
Number of subjects: 15
Study 21576560 — intervention group
Group type: EXPERIMENTAL
Intervention: ESS (all conditions)
Number of subjects: 15
Study 19164621 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq optical laryngoscope
Number of subjects: 200
Study 19164621 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 200
Study 16765179 — intervention group
Group type: EXPERIMENTAL
Intervention: alfuzosin 10 mg daily + tadalafil 20 mg
Number of subjects: 18
Study 16765179 — intervention group
Group type: COMPARATOR
Intervention: alfuzosin 10 mg daily + placebo
Number of subjects: 18
Study 15600378 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine (SNRI)
Number of subjects: 0
Study 15600378 — intervention group
Group type: COMPARATOR
Intervention: Selective serotonin reuptake inhibitors (SSRIs)
Number of subjects: 0
Study 11903327 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure lowering interventions in diabetic patients
Number of subjects: 0
Study 11903327 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors
Number of subjects: 0
Study 11903327 — intervention group
Group type: COMPARATOR
Intervention: Blood pressure lowering among non-hypertensive individuals
Number of subjects: 0
Study 11903327 — intervention group
Group type: COMPARATOR
Intervention: Different classes of drug for blood pressure lowering
Number of subjects: 0
Study 11903327 — intervention group
Group type: EXPERIMENTAL
Intervention: ADVANCE trial (Action in Diabetes and Vascular Disease)
Number of subjects: 0
Study 9684433 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide 100 mg twice daily
Number of subjects: 122
Study 9684433 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 75 mg b.i.d.
Number of subjects: 122
Study 7804515 — intervention group
Group type: EXPERIMENTAL
Intervention: Urapidil (60 mg)
Number of subjects: 24
Study 7804515 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin (2 mg)
Number of subjects: 24
Study 7804515 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg)
Number of subjects: 24
Study 7804515 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 3408928 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbocisteine
Number of subjects: 74
Study 3408928 — intervention group
Group type: EXPERIMENTAL
Intervention: Debrisoquine
Number of subjects: 74
Study 3408928 — intervention group
Group type: COMPARATOR
Intervention: Normal control population
Number of subjects: 74
Study 31044510 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Number of subjects: 0
Study 31044510 — intervention group
Group type: COMPARATOR
Intervention: Delayed implant placement combined with maxillary sinus floor elevation utilizing the transalveolar approach and nonsubmerged healing
Number of subjects: 0
Study 28467771 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line chemotherapy
Number of subjects: 80
Study 28467771 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CTC counts
Number of subjects: 80
Study 28467771 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of CTC enumeration after two cycles of chemotherapy
Number of subjects: 80
Study 26977135 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual homecare plus five additional nursing interventions at 48 and 72 hours and at 7, 14, and 21 days after discharge
Number of subjects: 103
Study 26977135 — intervention group
Group type: COMPARATOR
Intervention: Usual homecare
Number of subjects: 103
Study 24934732 — intervention group
Group type: EXPERIMENTAL
Intervention: LESS‐DN
Number of subjects: 100
Study 24934732 — intervention group
Group type: COMPARATOR
Intervention: LDN
Number of subjects: 100
Study 22250852 — intervention group
Group type: EXPERIMENTAL
Intervention: Contingency Management (CM)
Number of subjects: 130
Study 22250852 — intervention group
Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 130
Study 20073218 — intervention group
Group type: EXPERIMENTAL
Intervention: Wuhu Decoction (WHD)
Number of subjects: 60
Study 20073218 — intervention group
Group type: COMPARATOR
Intervention: Western medicine (fluticasone propionate)
Number of subjects: 60
Study 20073218 — intervention group
Group type: COMPARATOR
Intervention: Normal control (10 healthy infants)
Number of subjects: 60
Study 20073218 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (WHD and control)
Number of subjects: 60
Study 17536942 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual Focus Schema Therapy (DFST)
Number of subjects: 30
Study 17536942 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 Step Facilitation Therapy (12FT)
Number of subjects: 30
Study 17536942 — intervention group
Group type: COMPARATOR
Intervention: Both therapies (DFST and 12FT)
Number of subjects: 30
Study 15646222 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered artificial saliva for three weeks followed by APF gel application for four minutes and immersion in artificial saliva for another three weeks.
Number of subjects: 10
Study 15646222 — intervention group
Group type: COMPARATOR
Intervention: Buffered artificial saliva for three weeks without APF gel application.
Number of subjects: 10
Study 11704618 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka mixed with juice (average peak blood‐alcohol level to 0.045%)
Number of subjects: 12
Study 11704618 — intervention group
Group type: COMPARATOR
Intervention: Juice only (placebo condition)
Number of subjects: 12
Study 9972339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide)
Number of subjects: 0
Study 9972339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers
Number of subjects: 0
Study 9972339 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical carbonic anhydrase inhibitor (dorzolamide) in association with beta-blockers and miotics
Number of subjects: 0
Study 7832024 — intervention group
Group type: EXPERIMENTAL
Intervention: Leadership group (n = 79)
Number of subjects: 203
Study 7832024 — intervention group
Group type: COMPARATOR
Intervention: Nonleadership group (n = 124)
Number of subjects: 203
Study 3134314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the upper arm
Number of subjects: 56
Study 3134314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the chest
Number of subjects: 56
Study 3134314 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin ointment placed on the pelvis
Number of subjects: 56
Study 29486626 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced diagnosis threat (DT) condition
Number of subjects: 0
Study 29486626 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnosis threat (DT) condition
Number of subjects: 0
Study 29486626 — intervention group
Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study 27138769 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial-risk group (two FDR with colorectal cancer)
Number of subjects: 8498
Study 27138769 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial-risk group (one FDR diagnosed at ≥60 y)
Number of subjects: 8498
Study 27138769 — intervention group
Group type: EXPERIMENTAL
Intervention: Familial-risk group (one FDR diagnosed at <60 y)
Number of subjects: 8498
Study 27138769 — intervention group
Group type: EXPERIMENTAL
Intervention: Men (general population)
Number of subjects: 8498
Study 27138769 — intervention group
Group type: EXPERIMENTAL
Intervention: Women (general population)
Number of subjects: 8498
Study 27138769 — intervention group
Group type: COMPARATOR
Intervention: Average-risk group
Number of subjects: 8498
Study 24105403 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated risk calculations for postoperative nausea and vomiting (PONV)
Number of subjects: 11613
Study 24105403 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual (no automated risk calculations)
Number of subjects: 11613
Study 22090065 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% O(2) during contractions
Number of subjects: 10
Study 22090065 — intervention group
Group type: EXPERIMENTAL
Intervention: 40% O(2) during recovery
Number of subjects: 10
Study 22090065 — intervention group
Group type: COMPARATOR
Intervention: Room air (normoxia) throughout
Number of subjects: 10
Study 19904553 — intervention group
Group type: EXPERIMENTAL
Intervention: Body Mass Index (BMI)
Number of subjects: 325
Study 19904553 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-Hip Ratio (WHR)
Number of subjects: 325
Study 19904553 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist Circumference (WC)
Number of subjects: 325
Study 19032254 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard surgical method
Number of subjects: 0
Study 19032254 — intervention group
Group type: EXPERIMENTAL
Intervention: Minitrach II
Number of subjects: 0
Study 19032254 — intervention group
Group type: EXPERIMENTAL
Intervention: Quicktrach
Number of subjects: 0
Study 19032254 — intervention group
Group type: COMPARATOR
Intervention: Melker kit
Number of subjects: 0
Study 15742599 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 14657528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.0 mg/m2
Number of subjects: 256
Study 14657528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.3 mg/m2
Number of subjects: 256
Study 14657528 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib at 1.3 mg/m2 (in phase II study)
Number of subjects: 256
Study 10390554 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of dicyclomine chlorhydrate
Number of subjects: 48
Study 10390554 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg of dicyclomine chlorhydrate
Number of subjects: 48
Study 10390554 — intervention group
Group type: COMPARATOR
Intervention: No-drug control group
Number of subjects: 48
Study 8654625 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH analogue treatment (6 SC implants of 3.6 mg goserelin acetate depot every 28 days for 6 months)
Number of subjects: 53
Study 8654625 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy women)
Number of subjects: 53
Study 8485328 — intervention group
Group type: EXPERIMENTAL
Intervention: Total nutrient admixture (TNA) at the rate of 4‐5 g lipid/h for 5‐9 days (mean 6.7 days)
Number of subjects: 16
Study 8485328 — intervention group
Group type: EXPERIMENTAL
Intervention: Filtration of TNA
Number of subjects: 16
Study 8485328 — intervention group
Group type: COMPARATOR
Intervention: Control group (no filtration)
Number of subjects: 16
Study 3816916 — intervention group
Group type: EXPERIMENTAL
Intervention: Nisoldipine
Number of subjects: 19
Study 31727561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram for predicting lymph node invasion (LNI) after RALP
Number of subjects: 1654
Study 29757893 — intervention group
Group type: EXPERIMENTAL
Intervention: Early initiated everolimus
Number of subjects: 192
Study 29757893 — intervention group
Group type: COMPARATOR
Intervention: Control (no everolimus)
Number of subjects: 192
Study 24359045 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 20
Study 24359045 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 20
Study 22827935 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitative sports group exercise program for prostate cancer patients, conducted for 15 months starting 8-12 weeks after prostatectomy or combination therapy.
Number of subjects: 0
Study 22827935 — intervention group
Group type: COMPARATOR
Intervention: Control group (no participation in the intervention).
Number of subjects: 0
Study 21375023 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 80
Study 21375023 — intervention group
Group type: COMPARATOR
Intervention: Diovan (80 mg)
Number of subjects: 80
Study 18037738 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (aspirin, clopidogrel, cilostazol)
Number of subjects: 60
Study 18037738 — intervention group
Group type: COMPARATOR
Intervention: Dual therapy (aspirin and clopidogrel)
Number of subjects: 60
Study 16077266 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (first and second recordings)
Number of subjects: 101
Study 16077266 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (second and third recordings)
Number of subjects: 101
Study 16077266 — intervention group
Group type: EXPERIMENTAL
Intervention: 24‐h ambulatory blood pressure monitoring (normotensive patients)
Number of subjects: 101
Study 16077266 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous percentage values of declines in pressure during sleep
Number of subjects: 101
Study 12406382 — intervention group
Group type: EXPERIMENTAL
Intervention: TiN-coated instruments (Group B.1, B.2, B.3)
Number of subjects: 96
Study 12406382 — intervention group
Group type: EXPERIMENTAL
Intervention: Uncoated instruments (Group A.1, A.2, A.3)
Number of subjects: 96
Study 12406382 — intervention group
Group type: COMPARATOR
Intervention: Control instruments (A.C/B.C)
Number of subjects: 96
Study 10598301 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 10598301 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine
Number of subjects: 0
Study 7697307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-2 (IL-2; 6 x 10(6) IU)
Number of subjects: 70
Study 7697307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon alpha (IFN alpha; 2 x 10(7) U)
Number of subjects: 70
Study 7697307 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta (IFN beta; 6 x 10(6) U)
Number of subjects: 70
Study 2548967 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg itraconazole
Number of subjects: 78
Study 2548967 — intervention group
Group type: COMPARATOR
Intervention: 500 mg ultramicronized griseofulvin
Number of subjects: 78
Study 1099692 — intervention group
Group type: EXPERIMENTAL
Intervention: Three antimalarial drugs
Number of subjects: 744
Study 1099692 — intervention group
Group type: COMPARATOR
Intervention: Local population (control)
Number of subjects: 744
Study 28391452 — intervention group
Group type: EXPERIMENTAL
Intervention: PEERS® Social Skills Intervention
Number of subjects: 177
Study 26641243 — intervention group
Group type: EXPERIMENTAL
Intervention: GM-CSF (250 μg/m2/d)
Number of subjects: 61
Study 26641243 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination (Mutagrip 0.5 ml/d)
Number of subjects: 61
Study 26641243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 24060253 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast cancer education program (details not specified)
Number of subjects: 209
Study 21569994 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib plus paclitaxel
Number of subjects: 485
Study 21569994 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab plus paclitaxel
Number of subjects: 485
Study 19092693 — intervention group
Group type: COMPARATOR
Intervention: C(AFF) + NF
Number of subjects: 7
Study 19092693 — intervention group
Group type: COMPARATOR
Intervention: WAT
Number of subjects: 7
Study 19092693 — intervention group
Group type: EXPERIMENTAL
Intervention: C(AFF) + WAT
Number of subjects: 7
Study 19092693 — intervention group
Group type: COMPARATOR
Intervention: CES
Number of subjects: 7
Study 19092693 — intervention group
Group type: EXPERIMENTAL
Intervention: C(AFF) + CES
Number of subjects: 7
Study 19092693 — intervention group
Group type: EXPERIMENTAL
Intervention: C(AFF)
Number of subjects: 7
Study 16837720 — intervention group
Group type: EXPERIMENTAL
Intervention: beta‐arteether
Number of subjects: 138
Study 16837720 — intervention group
Group type: COMPARATOR
Intervention: alpha/beta‐arteether
Number of subjects: 138
Study 12571166 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant FSH (rFSH)
Number of subjects: 0
Study 11482712 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase‐contrast cine MR angiography
Number of subjects: 230
Study 11482712 — intervention group
Group type: COMPARATOR
Intervention: Control group (asymptomatic normals)
Number of subjects: 230
Study 9113180 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane-N2O
Number of subjects: 62
Study 9113180 — intervention group
Group type: COMPARATOR
Intervention: Propofol-N2O
Number of subjects: 62
Study 8364348 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxaprotiline
Number of subjects: 429
Study 8364348 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 429
Study 8364348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 429
Study 3721047 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar epidural analgesia (L.E.A.)
Number of subjects: 52
Study 3721047 — intervention group
Group type: COMPARATOR
Intervention: Control group (i.v. infusion of Hydralazine and MgSO4)
Number of subjects: 52
Study 30354704 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 1094
Study 30354704 — intervention group
Group type: EXPERIMENTAL
Intervention: Consensus OH
Number of subjects: 1094
Study 26674764 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc-biofortified rice (hydroponically enriched with (70)Zn)
Number of subjects: 16
Study 26674764 — intervention group
Group type: COMPARATOR
Intervention: Control rice fortified with (70)ZnSO4
Number of subjects: 16
Study 24770616 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote ischemic postconditioning (RiPoC)
Number of subjects: 60
Study 24770616 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study 22421496 — intervention group
Group type: EXPERIMENTAL
Intervention: Transnasal endoscopy (TNE)
Number of subjects: 95
Study 22421496 — intervention group
Group type: COMPARATOR
Intervention: Standard endoscopy (SE)
Number of subjects: 95
Study 20153122 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiotherapy (RT)
Number of subjects: 38
Study 18267181 — intervention group
Group type: EXPERIMENTAL
Intervention: CT screening for lung cancer
Number of subjects: 0
Study 18267181 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography and sputum cytology
Number of subjects: 0
Study 16087821 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate sodium (2.5 mg daily) plus ergocalciferol (1000 IU) and calcium (1200 mg)
Number of subjects: 500
Study 16087821 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ergocalciferol (1000 IU) and calcium (1200 mg)
Number of subjects: 500
Study 12700718 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg diazepam (DZP)
Number of subjects: 8
Study 12700718 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg diazepam (DZP)
Number of subjects: 8
Study 12700718 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 10582134 — intervention group
Group type: EXPERIMENTAL
Intervention: HD-EPI 120 mg/m2 + CP 60 mg/m2
Number of subjects: 228
Study 10582134 — intervention group
Group type: COMPARATOR
Intervention: VNR 25 mg/m2 + CP 60 mg/m2
Number of subjects: 228
Study 8729714 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Examination Therapy
Number of subjects: 28
Study 8729714 — intervention group
Group type: COMPARATOR
Intervention: Current Events comparison group
Number of subjects: 28
Study 1896818 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol
Number of subjects: 10
Study 1896818 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10
Study 1896818 — intervention group
Group type: COMPARATOR
Intervention: Labetalol
Number of subjects: 10
Study 7038354 — intervention group
Group type: EXPERIMENTAL
Intervention: Bazalin (yellow labeled tubes containing fluocinolone acetonide 0.025%, leucobitupal 5% and salicylic acid 3%)
Number of subjects: 22
Study 7038354 — intervention group
Group type: COMPARATOR
Intervention: Desoximetasone (red labelled tubes)
Number of subjects: 22
Study 31743184 — intervention group
Group type: EXPERIMENTAL
Intervention: Incentive-based game therapy
Number of subjects: 80
Study 31743184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 80
Study 29943647 — intervention group
Group type: EXPERIMENTAL
Intervention: WhatsApp application for diabetes education
Number of subjects: 0
Study 29943647 — intervention group
Group type: COMPARATOR
Intervention: Regular care (Control)
Number of subjects: 0
Study 27863598 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated laughter programme
Number of subjects: 40
Study 27863598 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study 24343388 — intervention group
Group type: EXPERIMENTAL
Intervention: Activated chlorine dioxide (CD) wound irrigation
Number of subjects: 193
Study 24343388 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (NS) wound irrigation
Number of subjects: 193
Study 23174912 — intervention group
Group type: EXPERIMENTAL
Intervention: XELOX plus bevacizumab (6 cycles) followed by either single-agent bevacizumab or XELOX plus bevacizumab until disease progression
Number of subjects: 394
Study 19476471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100 mg once daily
Number of subjects: 0
Study 19476471 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 25 mg once daily
Number of subjects: 0
Study 17459031 — intervention group
Group type: EXPERIMENTAL
Intervention: Single posterior subtenon injection of triamcinolone acetonide (40 mg in 1 ml) plus sham eyedrops (prednisolone acetate 1% vehicle)
Number of subjects: 40
Study 17459031 — intervention group
Group type: COMPARATOR
Intervention: Posterior subtenon sham injection (1 ml balanced salt solution) plus prednisolone acetate 1% eyedrops
Number of subjects: 40